CervoMed Inc (CRVO) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of CervoMed Inc stock $0.77, price $1.69, that is 54.4% below the price, quality 28 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
CervoMed Inc
CRVO · USFar too expensive (fair value 54% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $1.37 – $45.47 · fair‑value band $0.5800 – $0.9600 · the $1.69 price screens above the $0.7700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Every Wednesday you see whether CervoMed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Show moreShow less
The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Stock analysis
CervoMed Inc (CRVO) currently trades at $1.69, while our estimate is $0.7700, 54% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.5800 (bear) to $0.9600 (bull), the price of $1.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
CervoMed Inc reported revenue of $4.0M in FY2025 versus $0 in FY2021. Reported net income was −$27.0M in FY2025.
Key figures
Market cap $25.4M Micro · EPS (TTM) $−3.21 · Return on equity −132% · Return on assets (EBIT) −138% (5-year average) · Operating margin −334,925% · Free cash flow −$23.4M · Net cash $8.2M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 83% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −54%, CRVO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, one officer or director bought shares worth $3.0M, on Jun 11, 2026.
- BuyJoshua S BogerDirector, 10% owner955,414 shares at $3.14$3.0MJun 11, 2026
- BuyWilliam Robert ElderCFO, GC & Secretary3,500 shares at $8.36$29,250Nov 18, 2025
- BuyMatthew WintonChief Commercial and Business5,000 shares at $8.29$41,430Nov 18, 2025
- BuyJohn J AlamCEO & President, Director, 10% owner21,600 shares at $8.46$182,736Nov 17, 2025
- BuySylvie GregoireDirector, 10% owner21,600 shares at $8.46$182,736Nov 17, 2025
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare CervoMed Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs CRVO |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs CRVO |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs CRVO |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs CRVO |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs CRVO |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs CRVO |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs CRVO |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs CRVO |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs CRVO |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs CRVO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is CervoMed Inc (CRVO) overvalued or undervalued?
What is the fair value of CRVO?
What is the quality score of CRVO?
What is the price target for CervoMed Inc (CRVO)?
What is the CervoMed Inc stock forecast for 2026?
What is the intrinsic value of CervoMed Inc (CRVO)?
Is CervoMed Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of CRVO?
How much is CervoMed Inc worth?
What do the bullish and bearish scenarios say about CRVO?
How solid is the balance sheet of CervoMed Inc (CRVO)?
How far is CRVO from its 52-week high?
Which stocks are comparable to CervoMed Inc?
Is CervoMed Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of CervoMed Inc (CRVO)?
What should I pay attention to with CervoMed Inc right now?
Key figures of CervoMed Inc
How large is the market capitalisation of CervoMed Inc (CRVO)?
What are the earnings per share of CervoMed Inc (CRVO)?
What is the return on equity of CervoMed Inc (CRVO)?
What is the EBIT return on assets of CervoMed Inc (CRVO)?
What is the operating margin of CervoMed Inc (CRVO)?
How much free cash flow does CervoMed Inc (CRVO) generate?
How much net cash does CervoMed Inc (CRVO) hold?
Watch CervoMed Inc in the live analysis
One click puts CervoMed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.